Once this molecular testing method is validated in larger multicenter studies, cell-free DNA analysis of retinoblastoma may allow physicians to precisely identify germline RB1 or MYCN mutations and prepare personalized therapy regimens and family genetic counseling. The gene discussed is MYCN; the disease is retinoblastoma.